Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant in Pediatric Participants With Congenital Adrenal Hyperplasia
NCT07159841Phase 3Recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Mar 2030
- Modality
- Allosteric Modulators, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 13
01
Overview
A Phase 3 trial of atumelnant in congenital adrenal hyperplasia (CAH), sponsored by Crinetics Pharmaceuticals. Started Jan 2026; status: recruiting.
02
Drugs
atumelnant
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT07159841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159841.